TransCode Therapeutics ( (RNAZ)) just unveiled an announcement. On December 19, 2025, TransCode Therapeutics appointed veteran life sciences executive Jack E. Stover to its board of directors, ...

CK Life Sciences International is set to merge its subsidiary Polynoma with Nasdaq-listed TransCode Therapeutics, in a move expected to boost the pipeline of anticancer drugs, according to the biotech ...

(RTTNews) - TransCode Therapeutics (RNAZ) has entered into a definitive agreement to acquire Polynoma, a privately-held biotechnology immuno-oncology company. Polynoma is developing a late-stage ...

In a pair of deals, TransCode Therapeutics has bagged Polynoma and its phase 3 cancer vaccine, as well as a $25 million injection into its cash-strapped coffers—but in doing so, the company is trading ...

Investing.com -- TransCode Therapeutics (NASDAQ:RNAZ) stock surged 50% after announcing the acquisition of Polynoma and a $25 million strategic financing from a subsidiary of CK Life Sciences. The ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. TransCode Therapeutics ( (RNAZ)) has ...

What happens when a trusted tech brand makes a decision that fundamentally alters how its products are used? For Synology, the answer is unfolding in real-time, as its recent move to eliminate ...

BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA ...

TransCode Therapeutics (NASDAQ:RNAZ) announces to raise $10M through the purchase and sale of 10.25M shares of its common stock and warrants to purchase up to 10.25M shares of common stock priced ...

Microsoft PowerToys is a free application that brings a bunch of advanced features to Windows for power users. Some of those tools give you more control over your mouse and keyboard settings. Others ...

BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a micro-cap biotech company with a market capitalization of $3.3 million and trading near its 52-week low, has received approval from its Safety ...